C Diff Treatment

C Diff Treatment

1317 bookmarks
Custom sorting
GutMicrobiota Health on Twitter
GutMicrobiota Health on Twitter
Steven Johnson starts his talk highlighting the fact that recurrence is one of the major challenges to face: more than 60% to 65% recurrences after 3 or more C. difficile infection episodes @esnm_eu #GMFHCoverage pic.twitter.com/v8pZbNTfK0— GutMicrobiota Health (@GMFHx) October 12, 2022
·twitter.com·
GutMicrobiota Health on Twitter
GutMicrobiota Health on Twitter
GutMicrobiota Health on Twitter
Take-home messages from Prof. Iqbal on available management options for severe C. difficile infection @esnm_eu #GMFHCoverage pic.twitter.com/ZHowYyjwxf— GutMicrobiota Health (@GMFHx) October 12, 2022
·twitter.com·
GutMicrobiota Health on Twitter
Unmet Needs in Management of C. Difficile Infection (CDI) - Pharmacy Times
Unmet Needs in Management of C. Difficile Infection (CDI) - Pharmacy Times
Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).
·pharmacytimes.com·
Unmet Needs in Management of C. Difficile Infection (CDI) - Pharmacy Times
Unmet Needs in Management of C. Difficile Infection (CDI) - MD Magazine
Unmet Needs in Management of C. Difficile Infection (CDI) - MD Magazine
Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).
·hcplive.com·
Unmet Needs in Management of C. Difficile Infection (CDI) - MD Magazine
The Path to Least Recurrence: A Systematic Review and Meta-Analysis of Fidaxomicin versus Vancomycin for Clostridioides difficile Infection
The Path to Least Recurrence: A Systematic Review and Meta-Analysis of Fidaxomicin versus Vancomycin for Clostridioides difficile Infection
Our systematic review and meta-analysis found fidaxomicin was consistently associated with a lower risk of CDI recurrence than vancomycin. These results confirm CDI guideline recommendations and indicate that fidaxomicin may be preferred over vancomycin to minimize CDI recurrence across multiple cli …
·pubmed.ncbi.nlm.nih.gov·
The Path to Least Recurrence: A Systematic Review and Meta-Analysis of Fidaxomicin versus Vancomycin for Clostridioides difficile Infection
Emerging alternatives against Clostridioides difficile infection
Emerging alternatives against Clostridioides difficile infection
Clostridioides difficile infection (CDI) is a significant worry within healthcare institutions and the community. It is one of the leading agents causing severe diarrhea worldwide. Effective management is critical since the morbidity and mortality attributed to CDI have increased exponentially over …
·pubmed.ncbi.nlm.nih.gov·
Emerging alternatives against Clostridioides difficile infection
Emerging alternatives against Clostridioides difficile infection
Emerging alternatives against Clostridioides difficile infection
Clostridioides difficile infection (CDI) is a significant worry within healthcare institutions and the community. It is one of the leading agents causing severe diarrhea worldwide. Effective management is critical since the morbidity and mortality attributed to CDI have increased exponentially over …
·pubmed.ncbi.nlm.nih.gov·
Emerging alternatives against Clostridioides difficile infection
Reducing Recurrence and Complications Related to Clostridioides difficile Infection: A Panel Discussion Summary - PubMed
Reducing Recurrence and Complications Related to Clostridioides difficile Infection: A Panel Discussion Summary - PubMed
Mitigating the risk for readmission and recurrence will enhance C. diff infection care, safety, and outcomes to improve a patient's health care journey and quality of life. Case managers need to take a primary role in the transition and care coordination processes, including patient and support syst …
·pubmed.ncbi.nlm.nih.gov·
Reducing Recurrence and Complications Related to Clostridioides difficile Infection: A Panel Discussion Summary - PubMed
Reducing Recurrence and Complications Related to Clostridioides difficile Infection: A Panel Discussion Summary
Reducing Recurrence and Complications Related to Clostridioides difficile Infection: A Panel Discussion Summary
Mitigating the risk for readmission and recurrence will enhance C. diff infection care, safety, and outcomes to improve a patient's health care journey and quality of life. Case managers need to take a primary role in the transition and care coordination processes, including patient and support syst …
·pubmed.ncbi.nlm.nih.gov·
Reducing Recurrence and Complications Related to Clostridioides difficile Infection: A Panel Discussion Summary
DEINOVE présente des données sur #DNV3837 au congrès ESCMID/ASM à Dublin. L'utilisation du DNV3837 est un changement de paradigme potentiel pour le traitement de l'infection par #CDiff permettant de traiter l’intestin dans son ensemble. https://t.co
DEINOVE présente des données sur #DNV3837 au congrès ESCMID/ASM à Dublin. L'utilisation du DNV3837 est un changement de paradigme potentiel pour le traitement de l'infection par #CDiff permettant de traiter l’intestin dans son ensemble. https://t.co
DEINOVE présente des données sur #DNV3837 au congrès ESCMID/ASM à Dublin. L'utilisation du DNV3837 est un changement de paradigme potentiel pour le traitement de l'infection par #CDiff permettant de traiter l’intestin dans son ensemble.https://t.co/QFH7TOZ2me pic.twitter.com/u2DQJEwc7E— Deinove (@Deinove) October 5, 2022
·twitter.com·
DEINOVE présente des données sur #DNV3837 au congrès ESCMID/ASM à Dublin. L'utilisation du DNV3837 est un changement de paradigme potentiel pour le traitement de l'infection par #CDiff permettant de traiter l’intestin dans son ensemble. https://t.co
Gut microbiota and host inflammation states could pave the way for personalized treatments for ulcerative colitis remission
Gut microbiota and host inflammation states could pave the way for personalized treatments for ulcerative colitis remission
Ulcerative colitis is a chronic debilitating inflammatory bowel disease with no curative treatment currently available. INRAE scientists have developed a novel predictive model of disease progression in pediatric patients that integrates both gut microbiota and host inflammation data.
·gutmicrobiotaforhealth.com·
Gut microbiota and host inflammation states could pave the way for personalized treatments for ulcerative colitis remission
Fidaxomicin Use in the Pediatric Population with Clostridioides difficile - PubMed
Fidaxomicin Use in the Pediatric Population with Clostridioides difficile - PubMed
Clostridioides difficile infection (CDI) remains a devastating infection both in hospital settings and in the community. While a number of antibiotics have anti-C. difficile activity, fidaxomicin is unique as a minimally absorbed antibiotic with narrow spectrum of activity. These featu …
·pubmed.ncbi.nlm.nih.gov·
Fidaxomicin Use in the Pediatric Population with Clostridioides difficile - PubMed
Not sure what is the best advice you can offer to your patients in terms of fixing gut-related issues? This infographic summarizes what works based on sound science:
Not sure what is the best advice you can offer to your patients in terms of fixing gut-related issues? This infographic summarizes what works based on sound science:
Not sure what is the best advice you can offer to your patients in terms of fixing gut-related issues? This infographic summarizes what works based on sound science: pic.twitter.com/BghKOLgyfS— GutMicrobiota Health (@GMFHx) September 30, 2022
·twitter.com·
Not sure what is the best advice you can offer to your patients in terms of fixing gut-related issues? This infographic summarizes what works based on sound science:
The closely related terms “fiber”, “microbiota-accessible carbohydrates” (or MACs) and “prebiotics” probably sound familiar. But what exactly are they and how can they contribute to promoting health and abrogating disease by shaping the gut mi
The closely related terms “fiber”, “microbiota-accessible carbohydrates” (or MACs) and “prebiotics” probably sound familiar. But what exactly are they and how can they contribute to promoting health and abrogating disease by shaping the gut mi
The closely related terms “fiber”, “microbiota-accessible carbohydrates” (or MACs) and “prebiotics” probably sound familiar. But what exactly are they and how can they contribute to promoting health and abrogating disease by shaping the gut microbiome? https://t.co/4onLUef1Ev— GutMicrobiota Health (@GMFHx) September 27, 2022
·twitter.com·
The closely related terms “fiber”, “microbiota-accessible carbohydrates” (or MACs) and “prebiotics” probably sound familiar. But what exactly are they and how can they contribute to promoting health and abrogating disease by shaping the gut mi
Initial vancomycin versus metronidazole for the treatment of first-episode non-severe Clostridioides difficile infection - PubMed
Initial vancomycin versus metronidazole for the treatment of first-episode non-severe Clostridioides difficile infection - PubMed
Initial vancomycin was associated with a reduced rate of new incident infection in the treatment of adult inpatients with first-episode non-severe CDI. These findings support the use of initial vancomycin for all inpatients with CDI, when fidaxomicin is unavailable.
·pubmed.ncbi.nlm.nih.gov·
Initial vancomycin versus metronidazole for the treatment of first-episode non-severe Clostridioides difficile infection - PubMed
GutMicrobiota Health on Twitter
GutMicrobiota Health on Twitter
Are you ready to attend the next @esnm_eu webinar on the management of recurrence of C. difficile infection?🗣 Daniel Pohl, Steven Johnson & Tariq Iqbal.👉 Join us on 12th October: https://t.co/GUYnBtIJOc pic.twitter.com/HdNsXTRYVw— GutMicrobiota Health (@GMFHx) September 28, 2022
·twitter.com·
GutMicrobiota Health on Twitter
ECC Leiden on Twitter
ECC Leiden on Twitter
Now at #LDDC22 at @ECCLeiden ; come to the sesssion on the Future of Anti-Infectives to hear my perspective on the future of #cdiff therapeutics @cdiffFoundation @Leidenbsp https://t.co/ViXCpEWS7k— Wiep Klaas Smits (@SmitsLab) September 27, 2022
·twitter.com·
ECC Leiden on Twitter
Treatment with butyrate alleviates dextran sulfate sodium and Clostridium difficile-induced colitis by preventing activity of Th17 cells via regulation of SIRT1/mTOR in mice - PubMed
Treatment with butyrate alleviates dextran sulfate sodium and Clostridium difficile-induced colitis by preventing activity of Th17 cells via regulation of SIRT1/mTOR in mice - PubMed
Inflammatory bowel disease (IBD) patients are particularly vulnerable to infection with Clostridium difficile infection (CDI).Available treatments of IBD with CDI have not effective. Butyrate, the metabolites of microbiota, plays a vital role in maintaining immune homeostasis and potential drugs for …
·pubmed.ncbi.nlm.nih.gov·
Treatment with butyrate alleviates dextran sulfate sodium and Clostridium difficile-induced colitis by preventing activity of Th17 cells via regulation of SIRT1/mTOR in mice - PubMed
Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view? - PubMed
Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view? - PubMed
Recently, the recommendations for the treatment of Clostridioides difficile infection (CDI) have been updated. However, in addition to the clinical efficacy data, the drug of choice should ideally represent optimal antimicrobial stewardship, with an emphasis on rapid restoration of the gut microbiot …
·pubmed.ncbi.nlm.nih.gov·
Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view? - PubMed
anand v on Twitter
anand v on Twitter
“@HannahMeekID22 Had yet another patient today that couldnt afford #fidaxomicin on discharge... I hope GI and ID are practicing in the real 🌎 and not based on society guidelines that may not be able to be translated into clinical practice thanks to drug cost. #IDtwitter #cdiff”
·twitter.com·
anand v on Twitter
James Wilson, DO, FAWM on Twitter
James Wilson, DO, FAWM on Twitter
“The #cdiff #vancomycin vs #fidaxomicin topic continues onward! (I mean, who still uses Flagyl first line..? The studies the guidelines are based on don’t REALLY assess the mild diseases though…) #IDTwitter #MedTwitter #MedEd #idcrit”
·twitter.com·
James Wilson, DO, FAWM on Twitter